Wed, 8 July 2015
Novartis nabs approval for a drug that could revolutionize how we treat heart disease and CVS Health doubles down on its anti-tobacco stance. Our Motley Fool's Michael Douglass and Todd Campbell discuss what it means for the companies involved. |